IO Biotech and Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 With KEYTRUDA in Ph 2 Trial in Patients with Resectable Tumors
“We are pleased to extend our collaboration with Merck into this new exploration of IO102-IO103 in combination with pembrolizumab in earlier, neoadjuvant and adjuvant settings,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech. “IO102-IO103 has shown promising early clinical activity with a positive safety profile in melanoma thus far and, as highlighted in our Key Opinion Leader webinar this past spring, a compelling need remains among patients with advanced melanoma for effective treatments with reduced toxicity. We believe that the novel biology of IO102-IO103 represents a potential paradigm shift in the management of additional cancer types beyond melanoma, and we look forward to expanding our dataset to evaluate our medicine in combination with pembrolizumab in earlier neoadjuvant and adjuvant settings.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.